ES2396613T3 - Imidazopirazinas e imidazotriazinas sustituidas - Google Patents

Imidazopirazinas e imidazotriazinas sustituidas Download PDF

Info

Publication number
ES2396613T3
ES2396613T3 ES09751280T ES09751280T ES2396613T3 ES 2396613 T3 ES2396613 T3 ES 2396613T3 ES 09751280 T ES09751280 T ES 09751280T ES 09751280 T ES09751280 T ES 09751280T ES 2396613 T3 ES2396613 T3 ES 2396613T3
Authority
ES
Spain
Prior art keywords
alkyl
independently selected
substituted
cr8r9
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09751280T
Other languages
English (en)
Inventor
Andrew P. Crew
Meizhong Jin
Mridula Kadalbajoo
Andrew Kleinberg
Mark J. Mulvihill
Jing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2396613T3 publication Critical patent/ES2396613T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de acuerdo con la Fórmula I: en la que: A es CH o N; Q1 es -X1-Y1-Z1; o Q1 es: X1 es cíclico5-10, que puede estar sustituido con uno o más grupos G1 seleccionados independientemente; Y1 se selecciona entre >C(R2)R3, >C(OR2)R3, >C>=O, >C>=C(R2)R3, >C>=NR2, >C>=NOR2, >NR2, >O, >S(O)m; Z1 se selecciona entre cíclico5-10 o alcoxi C1-6, cualquiera de los cuales puede estar sustituido con uno o más gruposG1 seleccionados independientemente; y en la que cuando Y es >O y R1 es ciclobutilo, al menos uno de X o Z está sustituido; cada caso de G1 seselecciona independientemente entre halo, -CN, -CF3, -OCF3, -NO2, alquilo C1-6, cíclico3-6alquilo C0-6, -OR4, -NR4R5, -C(O)R4, -C(O)NR4R5, -C(O)OR4 o -NR4C(O)R5 , cualquiera de los cuales puede estar sustituido con uno o más grupos G2 seleccionados independientemente; cada caso de G2 se selecciona independientemente entre halo, -CN, -OH, -NH2, -NO2, oxo, -CF3, -OCF3 o alquilo C1-6, cualquiera de los cuales puede estar sustituido con uno o más grupos seleccionados independientemente entrehalo, -CN, -OH, -NH2, alquilo C1-6 (en el que cualquiera de los siguientes puede estar parcial o totalmentehalogenado), -Oalquilo C1-6 o -N(alquil C1-6) alquilo C1-6; cada caso de G3 se selecciona independientemente entre halo, oxo, -CN, -CF3, -OCF3, alquilo C1-6, cíclico3-6alquiloC0-6, -OR8, -NR8R9, -C(O)R8, -C(O)NR8R9, -C(O)OR8, -NR8C(O)R9, -(CR8R9)nNR6R7, -(CR8R9)nOR6, -NR8C(O)OR9, -O(CR8R9)nNR6R7, -N(CR8R9)nOR6 o - (CR8R9)nNR6C(O)OR7, cualquiera de los cuales puede estar sustituido con unoo más sustituyentes G2 seleccionados independientemente R1 se selecciona entre -SR2, alquilo C1-6, 5,6-bicíclicoarilo, o cíclico3-6, cualquiera de los cuales puede estar sustituidocon uno o más grupos G3 seleccionados independientemente; cada caso de R2 y R3 se selecciona independientemente entre H, halo o -alquilo C1-6; cada caso de R4, R5, R6, R7, R8, R9 se selecciona independientemente entre H, alquilo C1-6 o cíclico3-6alquilo C0-6; enlos que cualquier par R4/R5, R6/R7, R8/R9, junto con el átomo al que está unido, puede formar un cíclico3-6 quepueden incluir uno o más heteroátomos seleccionados entre O, N(alquilo C0-3) o S(O)m; cada m se selecciona independientemente entre 0-2; y cada n se selecciona independientemente entre 0-4; o una sal farmacéuticamente aceptable del mismo.
ES09751280T 2008-05-19 2009-05-18 Imidazopirazinas e imidazotriazinas sustituidas Active ES2396613T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5434508P 2008-05-19 2008-05-19
US54345P 2008-05-19
PCT/US2009/044325 WO2009143051A1 (en) 2008-05-19 2009-05-18 Substituted imidazopyr-and imidazotri-azines

Publications (1)

Publication Number Publication Date
ES2396613T3 true ES2396613T3 (es) 2013-02-22

Family

ID=40983400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09751280T Active ES2396613T3 (es) 2008-05-19 2009-05-18 Imidazopirazinas e imidazotriazinas sustituidas

Country Status (5)

Country Link
US (1) US8481733B2 (es)
EP (1) EP2283020B8 (es)
JP (1) JP2011520970A (es)
ES (1) ES2396613T3 (es)
WO (1) WO2009143051A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005230818B2 (en) 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
UA106692C2 (uk) 2011-02-23 2014-09-25 Пфайзер Інк. ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
BR112014000625B1 (pt) 2011-07-13 2019-03-19 BASF Agro B.V. Compostos, processos para a preparação de compostos, composições agroquímicas, usos dos compostos e método para o combate de fungos fitopatogênicos
PH12014500081A1 (en) 2011-07-15 2019-07-03 Basf Se Fungicidal alkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds
EP2731934A1 (en) 2011-07-15 2014-05-21 Basf Se Fungicidal alkyl- and aryl-substituted 2-[2-chloro-4-(dihalo-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds
EP2744794B1 (en) 2011-08-15 2015-12-30 Basf Se Fungicidal substituted 1-{2-cyclyloxy-2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-ethyl}-1h-[1,2,4]triazole compounds
KR20140080482A (ko) 2011-08-15 2014-06-30 바스프 에스이 살진균 치환된 1-｛2-［2-할로-4-(4-할로겐-페녹시)-페닐］-2-알콕시-3-메틸-부틸｝-1h-［1,2,4］트리아졸 화합물
EA201400231A1 (ru) 2011-08-15 2014-07-30 Басф Се Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-алкинил/алкенилэтил}-1н-[1,2,4]триазольные соединения
CN103374001B (zh) * 2012-04-19 2015-10-28 山东轩竹医药科技有限公司 咪唑并三嗪类mTOR抑制剂
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
EA030875B1 (ru) 2012-12-20 2018-10-31 Басф Агро Б.В. Композиции, содержащие триазольное соединение
BR112015016446B1 (pt) 2013-01-09 2019-10-29 Basf Agro Bv processo para preparar compostos de fórmula ii, solução aquosa e uso da solução aquosa
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
ES2860941T3 (es) 2013-07-08 2021-10-05 Basf Agro Bv Composiciones que comprenden un compuesto de triazol y un bioplaguicida
EP3057970A1 (en) * 2013-10-18 2016-08-24 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
CA2833867A1 (en) 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
EP3269245B1 (en) 2014-06-25 2023-08-16 BASF Agro B.V. Pesticidal compositions
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
WO2016106628A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
ES2912465T3 (es) * 2016-03-11 2022-05-26 Angel Pharmaceutical Co Ltd Compuestos y métodos para modular la tirosina quinasa de Bruton
WO2017157916A1 (en) 2016-03-16 2017-09-21 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
JP6903074B2 (ja) 2016-03-16 2021-07-14 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 穀類につく耐性植物病原菌類を駆除するためのテトラゾリノンの使用
WO2017157920A1 (en) 2016-03-16 2017-09-21 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
CN106831787B (zh) * 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
KR102627756B1 (ko) * 2017-03-22 2024-01-23 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 브루톤 타이로신 키나제 억제제
EP3675858B1 (en) * 2017-09-01 2023-04-26 OptiKira, LLC Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
JP2022517280A (ja) * 2019-01-18 2022-03-07 シービン リィアォ ブルトン型チロシンキナーゼ阻害剤
CA3133096A1 (en) * 2019-03-15 2020-09-24 Alterity Therapeutics Limited Compounds for and methods of treating diseases
MX2022008148A (es) * 2020-01-02 2022-07-21 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de btk.
WO2021184154A1 (en) * 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
US11155547B1 (en) 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
WO2024240242A1 (zh) * 2023-05-25 2024-11-28 正大天晴药业集团股份有限公司 含有酰胺取代的芳香环的化合物、其药物组合物及用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
WO1992021660A1 (en) 1991-05-29 1992-12-10 Pfizer, Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
MX9304801A (es) 1992-08-06 1997-06-28 Warner Lambert Co 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales.
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
MXPA01011632A (es) 1999-05-14 2002-11-07 Imclone Systems Inc Tratamiento de tumores refractarios humanos, con antagonistas de receptor del factor de crecimiento epidermico.
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CA2380904C (en) 1999-08-12 2009-02-10 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
WO2002045653A2 (en) 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
HUP0302544A3 (en) 2001-01-09 2012-09-28 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
JP2004534010A (ja) 2001-03-28 2004-11-11 ブリストル−マイヤーズ　スクイブ　カンパニー 新規なチロシンキナーゼ阻害剤
CA2449166A1 (en) 2001-05-08 2002-11-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-egfr antibodies and anti-hormonal agents
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
GB0122560D0 (en) 2001-09-19 2001-11-07 Aventis Pharma Ltd Chemical compounds
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20030175763A1 (en) 2001-12-20 2003-09-18 Degenhardt Yan Y. Identification of an amplified gene and target for drug intervention
US20050215564A1 (en) 2002-02-14 2005-09-29 Stiles Charles D Methods and compositions for treating hyperproliferative conditions
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
ATE353650T1 (de) 2002-04-16 2007-03-15 Astrazeneca Ab Kombinationstherapie zur behandlung von krebs
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
KR20070074667A (ko) 2003-03-12 2007-07-12 화이자 프로덕츠 인크. 피리딜옥시메틸 및 벤즈이속사졸 아자비시클릭 유도체
SG132683A1 (en) * 2003-10-15 2007-06-28 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2005230818B2 (en) 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
NZ551431A (en) 2004-06-03 2010-04-30 Hoffmann La Roche Treatment with cisplatin and an EGFR-inhibitor
WO2006004703A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
DE202005016343U1 (de) 2005-10-19 2007-02-22 Weidmüller Interface GmbH & Co. KG Elektrische Steckverbindung mit Schnellentriegelung
JP5335432B2 (ja) * 2005-11-17 2013-11-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 縮合２環系ｍＴＯＲ阻害剤
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP5512975B2 (ja) * 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
JP5372737B2 (ja) * 2006-03-13 2013-12-18 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
TW200900070A (en) 2007-02-27 2009-01-01 Osi Pharm Inc Combination cancer therapy

Also Published As

Publication number Publication date
EP2283020B1 (en) 2012-10-31
EP2283020A1 (en) 2011-02-16
WO2009143051A1 (en) 2009-11-26
US20090286768A1 (en) 2009-11-19
EP2283020B8 (en) 2012-12-12
JP2011520970A (ja) 2011-07-21
US8481733B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
ES2396613T3 (es) Imidazopirazinas e imidazotriazinas sustituidas
AR058700A1 (es) Compuestos heterociclicos como bloqueadores del canal de sodio epitelial
CO6251282A2 (es) Oxazolidinonas sustituidas y su uso
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
CO6321170A2 (es) Heterociclos fusionados de ciclobutoxi amino y usos terapeuticos de los mismos
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
ES2855732T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR071112A1 (es) Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.
MX2010013768A (es) Fosfatos ciclicos de nucleosidos.
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
PE20160869A1 (es) Derivados novedosos de amino pirimidina
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
AR067271A1 (es) Derivados de triazolona inhibidores no nucleosidos de la transcriptasa inversa, utiles para el tratamiento de enfermedades mediadas por el vih o el arc y composiciones farmaceuticas que los contienen.
ES2529691T3 (es) Derivados de 3-amino-imidazo [1,2-A] piridina como inhibidores de SGLT
AR076236A1 (es) Compuestos organicos y sus usos
AR087017A1 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение